MedTrace Logo

Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)

NCT05884372 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-11-24

No results posted yet for this study

Summary

Primary objective:

To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.

Secondary objective:

To compare the efficacy of denosumab with eldecalcitol or native vitamin D treatment in postmenopausal women with osteoporosis on bone turnover markers, serum PTH, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.

Conditions

  • Osteoporosis in Postmenopausal Women

Interventions

DRUG

Eldecalcitol

the same as arm descriptions.

DRUG

Native Vitamin D

the same as arm descriptions.

DRUG

Denosumab

the same as arm descriptions.

DRUG

Calcium

the same as arm descriptions.

Sponsors & Collaborators

  • Chugai Pharma China Co., Ltd.

    collaborator UNKNOWN

  • Xi'an Honghui Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-24
Primary Completion
2025-07-16
Completion
2025-07-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05884372 on ClinicalTrials.gov